Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

33.93USD
2 Dec 2016
Change (% chg)

$0.38 (+1.13%)
Prev Close
$33.55
Open
$33.87
Day's High
$34.00
Day's Low
$33.67
Volume
3,790,173
Avg. Vol
4,001,720
52-wk High
$59.00
52-wk Low
$30.89

Summary

Name Age Since Current Position

Goran Ando

67 2013 Chairman of the Board

Lars Rebien Soerensen

61 2015 President, Chief Executive Officer

Jeppe Christiansen

56 2013 Vice Chairman of the Board

Jesper Brandgaard

52 2000 Chief Financial Officer, Executive Vice President

Maziar Doustdar

45 2015 Executive Vice President, International Operations

Lars Fruergaard Joergensen

49 2014 Executive Vice President, Chief of Staff

Mads Krogsgaard Thomsen

55 2000 Chief Science Officer, Executive Vice President

Jakob Riis

50 2016 Executive Vice President, Head of North America Operations

Henrik Wulff

46 2015 Executive Vice President, Product Supply

Brian Daniels

56 2016 Director

Liselotte Hyveled

50 2014 Director, Employee Representative

Anne Kverneland

59 2000 Director, Employee Representative

Stig Stroebaek

52 1998 Director, Employee Representative

Soeren Thuesen Pedersen

51 2006 Director, Employee Representative

Bruno Angelici

69 2011 Independent Director

Sylvie Gregoire

54 2015 Independent Director

Liz Hewitt

59 2012 Independent Director

Mary Szela

52 2015 Independent Director

Peter Hugreffe Ankersen

2015 Corporate Vice President & Head of Investor Relations

Biographies

Name Description

Goran Ando

Dr. Goran A. Ando, M.D. has served as Chairman of the Board of Directors of Novo Nordisk A/S since March 20, 2013. He was Vice Chairman of the Company's Board from March 8, 2006 until March 20, 2013, and he has been Member of the Board of the Company since March 9, 2005. He has been Chairman of the Nomination Committee of the Company since April 2013 and Chairman of the Remuneration Committee since 2015. He was Chief Executive Officer (CEO) of Celltech Group plc in the United Kingdom until 2004. He joined Celltech from Pharmacia (currently Pfizer) where he was Executive Vice President and President of Research and Development with additional responsibilities for manufacturing, Information Technology, business development and Mergers & Acquisitions from 1995 to 2003. From 1989 to 1995, he was Medical Director, moving to Deputy Research and Development Director, and then Research and Development Director of Glaxo Group in the United Kingdom. He was also Member of the Glaxo Group Executive Committee. He is Specialist in General Medicine and Founding Fellow of the American College of Rheumatology in the United States. He serves as Chairman of the Board of Directors of Symphogen A/S and as Member of the Boards of Novo A/S, Molecular Partners AG, EUSA Pharma Ltd. and ICMEC. He also serves as Senior Advisor to Essex Woodlands Health Ventures Ltd. in the United Kingdom. He has qualifications and executive background within the international pharmaceutical industry. He qualified as Medical Doctor at Linkopings Universitet (the University of Linkoping) in 1973, and as Specialist in General Medicine at the same institution in 1978.

Lars Rebien Soerensen

Mr. Lars Rebien Soerensen no longer serves as Chief Executive Officer (CEO) and President at Novo Nordisk A/S effective as of by the end of 2016 (December 31, 2016). He has been CEO since November 2000 and he has served as President of the Company since April 2015. He also served as President of the Company from November 2000 until January 30, 2014. He joined the Company's Enzymes Marketing in 1982. Over the years, he has been stationed in several countries, including the Middle East and the United States. He was appointed Member of Corporate Management in May 1994, and was given responsibility for Health Care within Corporate Management in December 1994. He is Vice Chairman of the Boards of Directors of Carlsberg A/S. He received the French award Chevalier de l'Ordre National de la Legion d'Honneur in 2005. Since October 2007, he has been Adjunct Professor at the Faculty of Life Sciences of Koebenhavns Universitet (the University of Copenhagen). He holds a Master of Science degree in Forestry from Koebenhavns Universitet from 1981 and a Bachelor of Science degree in International Economics from Copenhagen Business School from 1983.

Jeppe Christiansen

Mr. Jeppe Christiansen has been Vice Chairman of the Board of Directors of Novo Nordisk A/S since March 20, 2013. He has been Member of the Remuneration and Audit Committees of the Company since 2015. He has been Chief Executive Officer of Fondsmaeglerselskabet Maj Invest A/S, Denmark, since 2009. He was Chief Executive Officer of LD Pensions from 2005 until 2009. Prior to that, he was Executive Director in Danske Bank from 1999 until 2004 with responsibility for group equity business and corporate international banking. From 1988 until 1999 he worked for LD Pensions, first as fund manager and later as deputy director with responsibility for the equity business. He is a Member of the Boards of Novo A/S, KIRKBI A/S, Symphogen A/S, as well as Vice Chairman of the Board of Haldor Topsoee A/S. He has background and experience within the financial sector, in particular in relation to financial and capital market issues, as well as insight into the investor perspective. He has a Master of Science in Economics from the University of Copenhagen (Koebenhavns universitet), Denmark, from 1985.

Jesper Brandgaard

Mr. Jesper Brandgaard has served as Chief Financial Officer (CFO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1999 as Senior Vice President of Corporate Finance. He serves as Chairman of the Boards of Directors at SimCorp A/S and NNIT A/S, both in Denmark. He holds a Master of Science degree in Economics and Auditing from 1990, as well as a Master of Business Administration degree from 1995, both from the Copenhagen Business School in Denmark.

Maziar Doustdar

Mr. Maziar Mike Doustdar has been Executive Vice President, International Operations at NOVO NORDISK A/S since April 2015. Maziar Mike Doustdar joined Novo Nordisk in 1992 as an office clerk in Vienna, Austria. He was appointed senior vice president of International Operations in 2013.

Lars Fruergaard Joergensen

Mr. Lars Fruergaard Joergensen has been appointed President and Chief Executive Officer of Novo Nordisk A/S effective as of January 1, 2017. He has previously served as Executive Vice President and Chief of Staff of Novo Nordisk A/S since November 24, 2014. He was Executive Vice President for Information Technology, Quality & Corporate Development of the Company from January 31, 2013 until November 24, 2014. He joined Novo Nordisk in 1991 as Economist in Health Care, Economy and Planning and has over the years completed overseas postings in the United States and Japan. In 2004, he was appointed Senior Vice President for IT (Information Technology) and Corporate Development. He is Chairman of the Board of NNE Pharmaplan A/S. He holds a Master of Science degree in Finance and Business Administration from Aarhus School of Business, Aarhus University (Aarhus Universitet), Denmark, from 1991.

Mads Krogsgaard Thomsen

Mr. Mads Krogsgaard Thomsen has served as Chief Science Officer (CSO) and Executive Vice President at Novo Nordisk A/S since November 2000. He joined the Company in 1991 and has been Head of Growth Hormone Research. He has been Head of Growth Hormone Research, Diabetes Research & Development, Global Drug Discovery. He has chaired Danish Research Council programs within endocrinology, and has served as President of the National Academy of Technical Sciences (ATV), Denmark. He sits on the Editorial Boards of international journals and is Member of the Board of Directors of University of Copenhagen, Denmark, as well as Chairman of the Board of Steno Diabetes Center A/S. He obtained a DMV degree in Veterinary Medicine from Koebenhavns Universitet in 1986, where he also obtained a Doctorate of Philosophy degree in 1989, and a Doctorate of Science degree in 1991. In 2000 he became Adjunct Professor of Pharmacology at the Royal Veterinary and Agricultural University (currently the Faculty of Health and Medical Sciences of the University of Copenhagen), Denmark.

Jakob Riis

Mr. Jakob Riis has served as Executive Vice President, Head of North America Operations at Novo Nordisk A/S since September 1, 2016. He has previously served as Executive Vice President, China, Pacific & Marketing at the Company since 2015. Before that, he has been Executive Vice President of Marketing, Medical Affairs and Stakeholder Engagement of Novo Nordisk A/S since November 24, 2014. He was Executive Vice President of Marketing & Medical Affairs of the Company from January 31, 2013 until November 24, 2014. He joined Novo Nordisk in 1996 as a health economist. From 2001 to 2005, he worked first in the United States sales force and then as Head of Marketing in Japan. In 2005, he was appointed Senior Vice President for International Marketing. He is also Chairman of the Board of Copenhagen Institute of Interaction Design and Member of the Board and Chair of Audit Committee of ALK-Abello A/S. He holds a Master of Science degree in Forestry from the Royal Veterinary and Agricultural University, Denmark (currently the Faculty of Science of the University of Copenhagen -Koebenhavns Univesitet) from 1992, where he also obtained a Doctorate of Philosophy degree in 1998.

Henrik Wulff

Mr. Henrik Ehlers Wulff has been Executive Vice President, Product Supply at NOVO NORDISK A/S since April 2015. Henrik Wulff joined Novo Nordisk in 1998 as a chemist. He was appointed senior vice president of Product Supply in 2013. He is Chair of the board of NN Pharmatech A/S and member of the boards of NNE Pharmaplan A/S and Ambu A/S, all in Denmark.

Brian Daniels

Liselotte Hyveled

Ms. Liselotte Hyveled has been Director, Employee Representative at NOVO NORDISK A/S since February 27, 2014. She has been Member of the Nomination Committee since 2015. She is project vice president for Novo Nordisk’s mealtime insulin projects faster-acting insulin aspart and liver-preference mealtime insulin in Global Development. She holds Master of Science (1992) from Copenhagen University, and Master of Medical Business Strategies (2011) from Copenhagen Business School, both in Denmark.

Anne Kverneland

Ms. Anne Marie Kverneland has been Employee Representative on the Board of Directors at Novo Nordisk A/S since November 2000. She has been Member of the Novo Nordisk Foundation since 2014. She joined the Company in July 1981. She is Laboratory Technician and union representative. She has a degree in Medical Laboratory Technology from Koebenhavns Universitet (Copenhagen University Hospital) in Denmark from 1980.

Stig Stroebaek

Mr. Stig Stroebaek has been Employee Representative on the Board of Directors at Novo Nordisk A/S since 1998. He has been Member of the Audit Committee of the Company since April 2013. He joined the Company in 1992 as Electrician. Mr. Stroebaek is Qualified Electrician and holds a diploma in further training for Members of the Boards of Directors from the Danish Employees’ Capital Pension Fund (LD) from 2003.

Soeren Thuesen Pedersen

Mr. Soeren Thuesen Pedersen has been Employee Representative on the Board of Directors at Novo Nordisk A/S since March 2006. He has been Member of the Remuneration Committee since 2015. He joined the Company in January 1994. He works as External Affairs Director in Quality Intelligence in the Company. He is Member of the Boards of HOFOR A/S, HOFOR Forsyning Holding PS, HOFOR Forsyning Komplementar A/S and HOFOR Forsyning A/S. He graduated with a Bachelor of Science degree in Chemical Engineering from Danmarks Ingenioerakademi, currently part of Danmarks Tekniske Univeristet in 1988.

Bruno Angelici

Mr. Bruno F. J. Angelici has served as Independent Member of the Board of Directors of Novo Nordisk A/S since March 23, 2011. He has been Member of the Nomination Committee of the Company since April 2013. He was Executive Vice President of AstraZeneca, with P&L responsibility for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa from 2001 until 2009. In 1998, he was appointed President of Zeneca, Japan. Previously, from 1989, he was President of Zeneca, France, having joined from Baxter International, where he held various management positions from 1978 to 1989. He is Member of the Board of Directors of Smiths Group plc and Wolters Kluwer, as well as Chairman of the Board of Vectura Group plc. Additionally, he is Member of the Global Advisory Board at Takeda Pharmaceutical Company Limited, Japan. He has global experience with two companies in the fields of pharmaceuticals and medical devices, as well as knowledge of strategy, sales, marketing and governance of main companies. He holds a Bachelor of Arts degree in Business Administration from Ecole Superieure de Commerce Reims from 1971. He graduated in Law from Universite de Reims Champagne Ardenne in 1973. In addition, he has a Master of Business Administration degree from Kellogg School of Management at NorthWestern University from 1978 and an AMP from Harvard Business School from 1993, both in the United States.

Sylvie Gregoire

Dr. Sylvie L. Gregoire, Ph.D. has been Independent Director of Novo Nordisk A/S since March 19, 2015. She has also been Member of the Audit Committee since 2015. She was President of Human Genetic Therapies, Shire plc, US and Switzerland, from 2007 to 2013. She is Member of the boards of Galenica AG and Perkin Elmer Inc., as well as Chairman of the strategic committee of Tarix Orphan LLC. She is also Advisor to the financial and biotech community. She has knowledge of the regulatory environment in both the US and the EU, having experience of all phases of the product life cycle, including discovery, registration, pre-launch and managing the life cycle while on the market. In addition, she has financial insight from i.a. P&L responsibility. She holds Pharmacy Doctorate degree (1986) from the State University of NY at Buffalo, US, BA in Pharmacy (1984) from Laval University, Canada, and Science College degree (1980) from Seminaire de Sherbrooke, Canada.

Liz Hewitt

Ms. Liz Hewitt has been Independent Member of the Board of Directors of Novo Nordisk A/S since March 21, 2012. She has been Chairman of the Company's Audit Committee since 2015 and Member of the Nomination Committee since April 2013. She was previously Group Director Corporate Affairs for Smith & Nephew plc from 2004 until 2011 and was involved at a senior level in all aspects of the business, including membership of Risk Committee of the company. From 1986 until 2004, she held a number of roles at 3i Group plc, from investing and syndicating private equity transactions to running the internal consultancy team, culminating her role as Director Corporate Affairs, when she was a Member of Risk Committee and a Trustee of the 3i Charitable Foundation. She qualified with Andersen & Co and also worked as a private equity investor for Citicorp Venture Capital (currently CVC) and Gartmore Investment Management Ltd. She serves as Member of the Board and Chair of Audit Committee of Savills plc. She is also Board Member and Chair of Nomination Committee of Melrose Industries plc and External Member of the Audit Committee of the House of Lords, the United Kingdom. She has experience within the field of medical devices, financial knowledge and knowledge of how international companies operate. She holds a Bachelor of Science degree with honors in Economics from University College London from 1977 and became Chartered Accountant FCA from the Institute of Chartered Accountants in 1982.

Mary Szela

Ms. Mary T. Szela has been Independent Director of Novo Nordisk A/S since March 19, 2015. She has also been Member of the Remuneration Committee. She is Member of the boards of Coherus Biosciences, Inc., Receptos Pharmaceuticals, Inc., Suneva Medical, Inc. and Aegerion Pharmaceuticals, Inc. She has understanding of the clinical, regulatory and marketing aspects of the pharmaceutical industry in North America, having both operational and strategic experience. She holds MBA (1991) from the University of Illinois at Chicago, US, and a Bachelor of Science in nursing degree (1985) from the University of Illinois at Chicago, US.

Peter Hugreffe Ankersen